Pharmaceuticals
-
MDGL Stock Soars on FDA Liver Disease Approval
FDA approves first-ever NASH treatment, Rezdiffra, by Madrigal Pharmaceuticals Inc (NASDAQ: MDGL). Breakthrough for millions suffering from liver...
-
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research...
-
Eli Lilly's Zepbound Shows Short-Lived Weight Loss Benefits
Uncover key investment insights in the dynamic obesity drug market. Discover growth, value, and momentum strategies in this evolving healthcare...
-
AbbVie Stock in Focus with Strategic Cerevel Acquisition
AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.
-
BAYRY Stock: Bayer Faces Major Legal and Drug Dev Setbacks
Bayer's legal and pharmaceutical setbacks are something investors should pay attention to. These issues could impact BAYRY stock value and guide...
-
Investors Watch as Novo Nordisk Pours Billions into Obesity Drugs
Novo Nordisk invests $2.3 billion in France to expand its weight-loss drug production, marking a significant move in the pharmaceutical industry.
-
FDA Approves Eli Lilly's Weight Loss Drug Zepbound
Eli Lilly's Tirzepatide drug, already approved for treating Type 2 diabetes as Mounjaro, has received FDA approval for weight management under the...
-
Gilead Sciences Marks Two Years of Robust Growth
Gilead Sciences reports robust Q3 growth, driven by oncology and HIV treatments, highlighting a solid pipeline and strategic expansion in global...
-
Exact Sciences Records Stellar Q3 2023 Results
Exact Sciences showcases robust Q3 results, marking a turning point with increased revenue, diversified streams, and an upward trajectory.
-
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, ON – November 1, 2023 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
-
EXACT Sciences Gears Up for Earnings Reveal
EXACT Sciences eyes a pivotal moment with its upcoming Q3 earnings report. The firm excels in ESG ratings and revenue, but operational costs raise...
-
Labor Dispute Hits CVS and Walgreens
A worker walkout at CVS and Walgreens poses investment questions. Learn more about potential impacts on retail investors.
-
IFF Eyes Billion-Dollar Pharma Unit Sale
IFF considers selling its pharma unit and Lucas Meyer cosmetics business. The sales could positively impact its debt profile and offer investment...
-
Are Biotech Penny Stocks Worth Investing In?
What can biotech penny stocks do for you? While investors might be attracted by the potential for outsize returns, there are serious risks to...
-
Understanding Drug Development and Approval Process
New drugs and treatments have to undergo a long process of development, clinical trials and FDA approvals before they can start bringing in revenue...
-
An Introduction to Biopharma: A New Era in Medicine
Discover the cutting-edge world of biopharmaceuticals and how it's reshaping healthcare. From advanced therapies to life-changing drugs, explore...
